Latest Accounting Standards News

Sigma Healthcare has completed a reverse acquisition merger with Chemist Warehouse, reporting $6 billion in revenue and declaring a fully franked dividend. The merger reshapes Australia’s pharmacy landscape with ambitious synergy targets and operational shifts.

Paragon Care Limited reported a robust 22% increase in revenue to $3.61 billion for FY25, driven by organic growth and key acquisitions including CH2 Holdings and Oborne Health Supplies. The company also refinanced its debt facilities and expanded into the dental market post-year-end.

EBOS Group Limited reported a 7% drop in revenue and a 21% fall in net profit for FY2025, reflecting ongoing cost pressures and restructuring impacts. The company declared a final dividend, signaling cautious optimism despite the earnings setback.

CVC Limited reports a stable FY2025 profit alongside a robust landbank poised for significant value uplift, targeting a net tangible asset per share of $5.75 through strategic rezoning and development.

Pacific Current Group reports a 47% drop in statutory profit amid major asset sales but boosts dividends and completes a $265 million share buy-back, positioning for growth in FY26.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Close the Loop Limited reported a 7% decline in revenue to $195.1 million for FY25, alongside a significant net loss increase to $21.9 million, driven by operational challenges and one-off costs. The company is navigating leadership changes and portfolio adjustments while maintaining a focus on sustainability and circular economy growth.

Charter Hall Group reported a mixed FY25 financial performance, with revenue declining but operating earnings and dividends increasing, highlighting resilience amid challenges.

National Storage REIT reported solid financial growth for FY25, with revenue up 10% and net profit rising 3%, alongside a final distribution declaration.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Bendigo and Adelaide Bank reveals a substantial $539.5 million goodwill impairment and $9 million restructuring costs for FY25, while reassuring investors that cash earnings and capital remain intact.

Stockland has reported a remarkable 170.6% increase in net profit for FY25 alongside steady revenue growth and fresh dividend declarations, signaling robust momentum in the property trust sector.